Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiretroviral Intensification for Cognitive Impairment in HIV
NCT02519777Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in HIV-associated neurocognitive disorder (HAND) comparing Placebo, Dolutegravir and Dolutegravir + Maraviroc (3 arms). Primary endpoint: Change in Normalized Composite Neurocognitive Test Score at 48 weeks. Started Apr 2016; status: completed.
02
Drugs
dolutegravirmaraviroc
03
Conditions
HIV-associated neurocognitive disorder (HAND)
Beyond the preview
Go deeper on NCT02519777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519777.